Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan with G-CSF and Radiation in Childhood Brainstem Glioma
NCT00107471Phase 2Terminated
- Sponsor
- Children's Oncology Group
- Start
- Oct 2005
- Primary completion
- Oct 2007
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 4
01
Overview
Phase 2, open-label trial of topotecan liposome in diffuse intrinsic pontine glioma (DIPG) (2 arms), sponsored by Children's Oncology Group. Primary endpoints: Feasibility of escalating the dose of topotecan, Dose-limiting toxic effects and 4 more. Started Oct 2005; status: terminated.
02
Drugs
topotecan liposome
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT00107471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107471.